ENSC Ensysce Biosciences, Inc.: Net earnings per share for the last 12 months

Ensysce Biosciences (ENSC) is accelerating formula discovery through the automation of laboratory tests. This annual EPS TTM chart illustrates the rate of change in earnings per share, where 27.20 determines the current status of the parameter. TAAP and MPAR technologies create a closed patent environment, locking clinics into the company's protocols, while development relies on academic alliances without mergers.

Ensysce Biosciences Inc. (ENSC): Earnings per share for the last twelve months from 02/11/2024 to 11/13/2026

Financial and market metric breakdowns for Ensysce (ENSC)

- current price and projected stock value:

Price Performance Chart Ensysce Biosciences|ENSC - Price Target Chart

- company stock capitalization data:

Market Valuation Ensysce Biosciences Inc.|ENSC - Enterprise Value

- book capitalization data:

Net Asset Value per Share Ensysce Biosciences|ENSC - Company Book Value|Capitalization to Book Value Ratio ensysce.com|ENSC - Aggregate Company Assets

- company total debt and liquidity indicators:

- net income and valuation ratios data:

ENSC - Net Income|Expected Net Income Ensysce Biosciences|ENSC - P/E Multiple|Future Price to Earnings Ensysce Biosciences|ENSC - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ensysce Biosciences Inc.|ENSC - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Ensysce Biosciences|ENSC - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months ensysce.com|ENSC - Earnings growth in current year|Expected earnings per share growth for next year Ensysce Biosciences

Initial company analysis:ENSC (Ensysce Biosciences, Inc.)

Original product of Ensysce Biosciences Inc.

This indicator calculates the percentage change in net income per share over the last twelve months relative to the same period last year. This metric determines the rate of capital generation and the fundamental resilience of the business to market volatility. For Ensysce Biosciences (ENSC), such dynamics reflect the commercialization efficiency of the TAAP and MPAR platforms in combating the opioid crisis. Investors should evaluate the annual EPS TTM delta as an indicator of the scalability of the company's innovative technologies. Negative trends in the annual EPS TTM delta may signal high R&D expenditures.

Competitor analysis for Ensysce Biosciences